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  Topical bladder instillation therapy with 10，000 units ofNCS was performed on 22 patients with
bladder tumors． One course of the therapy consisted of the instillation for 20 times．
  The following results were obtained：
1） NCS was not detected in the serum before and after the instillation in the selected 3 patients． ln
 the tumors NCS level was slightly higher than that in the serum．
2） In 4 （180／，） of the 22 patients the tumors disappeared completely． One patient （50／．） showed
 partial disappearance and remaining 17 patients （77e／，） no response． Therefore， the total respense
 rate was 23 per cent．
3） Frorn our studies， this therapy was thought to be effective in low stage， low grade， papillary and
 single tumors of small size．
4） The local side effects were observed in 10 patients （450／．）， while no general untoward effect was
 observed．
       1 は じ め に










































 悪性度はtransitional cell papilloma 10例， trans－
itional cell carcinoma Grade I 5例， Grade II 5
例，Gradc III 2例であり，浸潤度はstage O 8例，

















 悪性度別にみると，transitional cell papillo、na 10例
申4例（40％）と，transitional cell carcinoma Grade
II 5例中1例（20％）に有効例が認められたが，
transitional cell carcinoma Grade 15例およびGra－
de III 2例においては，有効例が認められなかった
（Table 2）．









Table 1．Serum and tissue level of NCS after the instillation into the urinary bladder in
patients with bladder tumors．
No， ot
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Table 2． Grade and effect
   No． of CompleteGrade   patients disappearance
Partial No Etfective


























日目ble 3． Stage and effect
    No． of CompleteStoge   potients disappearance
Partial No Etfectlve

























Table 4． Tumor size and effect
      No． ofTumor size      patients
Complete Partial No Effective





























Table 6． Tumor number and effect
No． of No， of Comp［ete Partial No Effective






















































































成績（Table 7）5～11）と比較してみると， mitomycin C，
adriamycin，5－FUよりその効果は劣ると思われた．
 つぎに副作用についてみると，局所的副作用が三半
Table 7．Results of bladder instillation thera－
pies in our clinic （1975一一1980）
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